Urine Cytology Rarely Escalates Clinical Management in the Surveillance of Non–muscle-Invasive Bladder Cancer

Nathan Feiertag, Emily Barry, Max Abramson, Ju young Park, Evan Kovac, Ahmed Aboumohamed, Kara Watts, Alex Sankin

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Introduction: The use of urine cytology in the surveillance of non–muscle invasive bladder cancer (NMIBC) is widely variable in clinical practice. We studied the impact of surveillance urine cytology on clinical decision making during NMIBC surveillance. Methods: A retrospective chart review was conducted on patients surveilled for clinical NMIBC from 2013 to 2020 with at least one follow-up cytology result after diagnosis. Patients were classified into risk categories according to American Urological Association (AUA) NMIBC guidelines. Data were obtained regarding tumor recurrence pathology and the frequency and findings of surveillance cystoscopies and urine cytologies. Positive (suspicious, malignant) and negative (atypical or negative for malignant cells) cytology results were correlated with cystoscopy and pathology findings when obtained within 3 months of the cytology specimen to determine if cytology impacted plan of care. Results: Two hundred fourteen patients with NMIBC were followed for a median of 34 months, with 1045 urine cytologies collectively obtained over the surveillance period. There were no positive urine cytologies among patients with low-risk NMIBC; therefore, cytology did not change management in this cohort. The potential for cytology to escalate management for patients of any risk group (ie, positive cytology in the absence of positive cystoscopy or pathology findings) occurred in 30 (2.9%) cases. However, clinical decision making was only altered in 4 cases (0.4% of all cytologies). Conclusions: Less than 1% of urine cytology specimens collected during NMIBC surveillance impacted clinical management, none of whom had low-risk disease. The use of urine cytology for surveillance of low-risk NMIBC should continue to be strongly discouraged, as it did not change management in any such cases.

Original languageEnglish (US)
Pages (from-to)258-264
Number of pages7
JournalClinical Genitourinary Cancer
Issue number2
StatePublished - Apr 2023


  • Transurethral resection of bladder tumor
  • non muscle invasive bladder cancer
  • urine cytology
  • urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Urine Cytology Rarely Escalates Clinical Management in the Surveillance of Non–muscle-Invasive Bladder Cancer'. Together they form a unique fingerprint.

Cite this